EGFR Bispecific Antibody Patent Grant - Amunix Pharmaceuticals
Summary
The USPTO granted patent US12590159B2 to Amunix Pharmaceuticals covering compositions targeting EGFR, including protease-activatable bispecific fusion proteins such as T cell engagers. The patent includes 8 claims for antibody binding domains targeting CD3 and EGFR, cleavable linker sequences, and methods of treatment for conditions such as cancer.
What changed
The USPTO granted patent US12590159B2 to Amunix Pharmaceuticals, Inc. covering compositions targeting epidermal growth factor receptor (EGFR) and methods for making and using the same. The patent specifically claims antibody binding domains for CD3 T cell receptor and EGFR, cleavable linker sequences, and protease-activatable bispecific fusion proteins including T cell engagers, with potential applications in treating cancer (A61P 35/00). The patent contains 8 claims and was granted March 31, 2026.
Pharmaceutical companies and researchers developing bispecific antibodies or T cell engager therapies should review the patent claims to assess potential freedom-to-operate concerns or licensing opportunities. Competitors in the EGFR and CD3 bispecific space should evaluate whether their technologies may fall within the scope of these granted claims.
What to do next
- Review patent claims (US12590159B2) to assess freedom-to-operate for bispecific antibody programs targeting EGFR
- Evaluate potential licensing needs if developing similar protease-activatable T cell engagers
- Monitor for any patent challenges or reexamination proceedings
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions targeting epidermal growth factor receptor and methods for making and using the same
Grant US12590159B2 Kind: B2 Mar 31, 2026
Assignee
Amunix Pharmaceuticals, Inc.
Inventors
Viktoriya Dubrovskaya, Eric Johansen, Sina Khorsand, Lucas Liu, Volker Schellenberger, Milton To, Tracy Young, André Frenzel, Philipp Kuhn
Abstract
The disclosure describes antibody binding domains for cluster of differentiation 3 T cell receptor (CD3), antibody binding domains for epidermal growth factor receptor (EGFR), cleavable linker sequences, and protease-activatable bispecific fusion proteins such as protease-activatable T cell engagers, as well as uses and methods of treatment.
CPC Classifications
C07K 16/2863 C07K 7/06 C07K 7/08 C07K 16/2809 C07K 2317/24 C07K 2317/31 C07K 2317/569 C07K 2317/622 C07K 2319/30 C07K 2319/50 A61P 35/00 A61K 2039/505
Filing Date
2025-02-25
Application No.
19063195
Claims
8
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.